Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.725 SEK | -3.62% | -10.05% | +2.69% |
Sales 2024 * | 65.08M 5.96M | Sales 2025 * | 471M 43.12M | Capitalization | 1.74B 159M |
---|---|---|---|---|---|
Net income 2024 * | -291M -26.65M | Net income 2025 * | 105M 9.61M | EV / Sales 2024 * | 28.3 x |
Net Debt 2024 * | 103M 9.4M | Net cash position 2025 * | 61.97M 5.67M | EV / Sales 2025 * | 3.56 x |
P/E ratio 2024 * |
-6.25
x | P/E ratio 2025 * |
8.69
x | Employees | 28 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.61% |
Latest transcript on Egetis Therapeutics AB
1 day | -3.62% | ||
1 week | -10.05% | ||
Current month | -14.22% | ||
1 month | -13.05% | ||
3 months | -3.86% | ||
6 months | +17.90% | ||
Current year | +2.69% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 17-06-15 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 17-12-30 |
Chief Tech/Sci/R&D Officer | - | 22-05-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mats Blom
BRD | Director/Board Member | 59 | 21-03-31 |
Director/Board Member | 50 | 19-12-31 | |
Thomas Lönngren
CHM | Chairman | 73 | 21-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 5.73 | -3.54% | 565 965 |
24-04-25 | 5.94 | +0.17% | 152,280 |
24-04-24 | 5.93 | -5.57% | 271,959 |
24-04-23 | 6.28 | +0.32% | 137,986 |
24-04-22 | 6.26 | -1.73% | 180,763 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 10:42 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.69% | 159M | |
-2.34% | 103B | |
+0.92% | 95.71B | |
+2.01% | 22.02B | |
-16.72% | 20.9B | |
-8.98% | 17.85B | |
-42.83% | 16.21B | |
-14.94% | 15.52B | |
+3.43% | 13.86B | |
+34.49% | 12.04B |
- Stock Market
- Equities
- EGTX Stock